Orezone Reports Q2-2025 Production and Hard Rock Expansion Update 
Malaysia and France Strengthen Defence Industry Ties with Landmark MoU Signing Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Basel, Switzerland, April 21, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved…
Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
Saint-Herblain (France), April 21, 2021 – Valneva SE, a specialty vaccine company focused on the…
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination…
22nd Century Group Issues Annual Letter to Shareholders
Company’s Confidence in MRTP Authorization is High; Launch of VLN® is Only the Beginning for…
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Bagsværd, Denmark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase…
Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8:00 a.m. ET
WARREN, N.J., April 21, 2021 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer
TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the…
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical…
Vericel to Report First-Quarter 2021 Financial Results on May 5, 2021
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced…
Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
RMAT Designation Follows Proof-of-Concept Data from ALLO-715 UNIVERSAL Trial in Heavily Pretreated, Refractory Multiple Myeloma…
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
– 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference…
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization
Primary efficacy in the second interim analysis demonstrates COVAXIN to be 78% effective after the…
Summit Therapeutics Announces Commencement of Rights Offering
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA,…
Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health
MONTREAL, April 21, 2021 (GLOBE NEWSWIRE) — ExCellThera Inc., a clinical-stage cell and molecular medicine…
Enzo’s Universal AMPICOLLECT™ Used on GENFLEX® Molecular Platform Cleared for Distribution by FDA Under Emergency Use Authorization
Company’s specimen collection kit now available for use in COVID-19 testing in the U.S. Sample…
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
Adverum Slate Background Adverum Slate Background Adverum Board Matrix Adverum Board Matrix Sonic’s Nominees Lack…
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
CLASSICAL-Lung study evaluated pepinemab in combination with the checkpoint inhibitor BAVENCIO® for the treatment of…
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) — SmallCapVoice.com Inc. (“SCV”) announces the availability of…
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma
REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…
Pharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416
Company on track to initiate prophylactic study of PHVS416 ZUG, Switzerland, April 21, 2021 (GLOBE…